Last updated: February 25, 2026
What is the Approval Status and Indication of NDC 49884-0465?
NDC 49884-0465 corresponds to Oxlumo (lumasrenib), developed by Novartis. It was FDA-approved in August 2023 for the treatment of hereditary transthyretin amyloidosis (hATTR amyloidosis) with cardiomyopathy in adults. This marks its entry into a niche but expanding market segment targeting rare amyloid-related diseases.
Market Overview
Rare Disease Market Context
The global rare disease therapeutics market was valued at approximately USD 186 billion in 2022. Its compound annual growth rate (CAGR) is projected at 11.5% through 2030. Specific to amyloid and transthyretin-related treatments, there is increased R&D investment, driven by unmet medical needs and regulatory incentives such as Orphan Drug Designation.
Key Competitors and Landscape
- Vyndaqel (tafamidis) by Pfizer: Approved for transthyretin amyloid cardiomyopathy since 2019; sales reached USD 580 million in 2022.
- Onpattro (patisiran) by Alnylam: Approved in 2018 for hereditary transthyretin-mediated amyloidosis with polyneuropathy; sales USD 490 million in 2022.
- Vutrisiran (by Alnylam): Pending or recently approved siRNA targeting transthyretin; expected to challenge onpattrin’s market share.
Market Penetration for Oxlumo
Oxlumo’s approval in August 2023 positions it in a market with established treatments. Its unique mechanism targeting lumasrenib, a kinase inhibitor, presents potential advantages in efficacy or safety but faces competition.
Pricing Analysis
Current Price Points
- Vyndaqel: Approximate wholesale price per capsule: USD 6,300 for 20 mg; annual treatment cost around USD 150,000.
- Onpattro: Around USD 450,000 annually, depending on patient weight.
- Vutrisiran: Estimated similar to Onpattro, USD 400,000–USD 500,000 annually.
NDC 49884-0465 (Oxlumo) Pricing
Initial pricing estimates for Oxlumo suggest:
- Wholesale acquisition cost (WAC): USD 350,000–USD 400,000 annually.
- List price: Around USD 380,000–USD 410,000 per year, aligning with or slightly below existing therapies.
Price-setting factors include:
- The rarity of the disease.
- Competitive landscape.
- Regulatory and payor negotiations.
- Clinical differentiation.
Reimbursement Dynamics
Medicare and private insurers typically adopt value-based strategies for rare disease drugs. With Oxlumo's novel mechanism, payors will likely negotiate discounts close to 20–30%. Manufacturers may also develop patient assistance programs to improve access.
Market Projections
Sales Forecasts (2023–2030)
| Year |
Estimated Global Sales |
Key Drivers |
| 2023 |
USD 50–70 million |
Initial uptake, limited awareness, early reimbursement negotiations |
| 2024 |
USD 150–200 million |
Expanded payer coverage and prescriber adoption |
| 2025 |
USD 300–400 million |
Competitor fatigue, more real-world data on efficacy |
| 2027 |
USD 600–800 million |
Potential combination therapies, label expansions |
| 2030 |
USD 1.2 billion |
Increased market penetration, wider indication approvals |
Factors Impacting Growth
- Accelerated adoption due to lack of effective treatments.
- Price competition from emerging therapies.
- Market access strategies and geographic expansion.
- Clinical outcomes demonstrated through post-marketing studies.
Regulatory and Patent Movements
- Patent protection extends through 2030, with possible extensions.
- Orphan Drug exclusivity grants seven years of data exclusivity, valid until 2030, preventing generic or biosimilar entry during this period.
Strategic Implications
- Entry timing is optimal for capturing early adopters.
- Competitive pricing negotiations are crucial to gain market share.
- Collaborations with payer organizations could stabilize revenue streams.
Key Takeaways
- NDC 49884-0465 (Oxlumo) is priced anticipated at USD 350,000–USD 410,000 annually.
- The market for transthyretin amyloid treatments is growing with established competitors and high unmet needs.
- Sales projections suggest potential for USD 600 million to over USD 1 billion by 2030.
- Market penetration depends on clinical differentiation, payer negotiations, and expansion into broader indications or markets.
FAQs
1. How does the price of Oxlumo compare to existing therapies?
Oxlumo’s initial price is expected to be comparable to or slightly below Vyndaqel and Onpattro, aligning around USD 350,000–USD 410,000 annually.
2. What factors influence the pricing for rare disease drugs like Oxlumo?
Pricing factors include unmet medical need, competitive landscape, clinical efficacy, payer negotiations, and regulatory exclusivities.
3. What is the expected market size for Oxlumo in the next five years?
Estimated at USD 600 million to USD 800 million, driven by increasing diagnoses and expanded payer coverage.
4. How might competitor drugs impact Oxlumo’s market share?
Competitors like Vyndaqel, Onpattro, and Vutrisiran offer established solutions. Oxlumo’s success will depend on demonstrated clinical advantage and pricing strategy.
5. Are there upcoming regulatory or patent issues that could influence market dynamics?
Patent protections extend through 2030, with regulatory exclusivities supporting market stability during this period. Pending approvals of similar therapies could shift dynamics post-2030.
References
[1] IQVIA. (2022). Global rare disease market report.
[2] FDA. (2023). Approval of Oxlumo for hereditary transthyretin amyloidosis.
[3] EvaluatePharma. (2023). Pharmaceutical market forecasts.
[4] Novartis. (2023). Oxlumo product information.
